Limitations, agreements, and source contact

Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers · Source last updated 2025-02-17

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement

pi Sponsor Employee

false

restrictive Agreement

false

limitations And Caveats

description

The study was completed with a small number of subjects analyzed.

point Of Contact

email

egordon@sarcomaoncology.com

organization

Sarcoma Oncology Research Center

phone

310-552-9999

title

Erlinda M. Gordon, MD/Principal Investigator

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice